nach oben

Erschienen in:

2010 | OriginalPaper | Buchkapitel

6. Reducing the Ecological Footprint of Pharmaceutical Usage: Linkages Between Healthcare Practices and the Environment

verfasst von : Christian G. Daughton, Ilene S. Ruhoy

Erschienen in: Green and Sustainable Pharmacy

Verlag: Springer Berlin Heidelberg

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

The design of pharmaceuticals and the practices surrounding the lifecycle of their manufacture and usage are central to minimize their impacts on the environment and increase the sustainability (see Kümmerer, Chaps. 1 and Chaps. 9, this book) of healthcare. Cradle-to-cradle design, as conceptualized by McDonough and Braungart, could play a key role in redesigning healthcare and reducing its environmental footprint (Daughton 2003). This chapter examines the following thesis involving the environmental sustainability of medication usage: “When actions designed to reduce the potential for environmental impact are integrated within the existing systems of pharmacopeia, pharmacy, and healthcare, significant natural collateral outcomes include improvements in the quality and efficiency of healthcare and in human well-being.” The major factors that could shape the future for sustainability of healthcare are discussed.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel Creating a Sustainability Culture – A (Human Resources) Management Perspective for Sustainable Pharmacy

Nächstes Kapitel Ecopharmacostewardship – A Pharmaceutical Industry Perspective

Adam GIR, Sanders R, Jonsson J (1999) The development of pharmacogenomic models to predict drug response. Trends Biotechnol 17, 30–33CrossRef

Anonymous (2008) List of withdrawn drugs. Wikipedia. http://en.wikipedia.org/wiki/List_of_withdrawn_drugs

Baird D (2003) Veterinary medicines in natural ecosystems: Assessing the risks. J Vet Pharmacol Therapeut 26, 28–29

Bajcar JM, Kennie N, Einarson TR (2005) Collaborative medication management in a team-based primary care practice: An explanatory conceptual framework. Res Social Adm Pharm 1, 408–429CrossRef

BCG (December 2003) The hidden epidemic: Finding a cure for unfilled prescriptions and missed doses. The Boston Consulting Group. http://www.bcg.com/impact_expertise/publications/files/Hidden_Epidemic_Finding_Cure_Unfulfilled_Rx_Missed_Doses_Dec2003.pdf

Berenguer B, La Casa C, de la Matta MJ, Martin-Calero MJ (2004) Pharmaceutical care: Past, present and future. Curr Pharm Des 10, 3931–3946CrossRef

Bernini P, Bertini I, Luchinat C, Nepi S, Saccenti E, Schäfer H, Schütz B, Spraul M, Tenori L (2009) Individual human phenotypes in metabolic space and time. J Proteome Res 8, 4264–4271

Borisy AA, Elliott PJ, Hurst NW, Lee MS, LehÃ¡r J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR, Keith CT (2003) Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 100, 7977–7982CrossRef

Boxall ABA (2002) The environmental side effects of medication – How are human and veterinary medicines in soils and water bodies affecting human and environmental health? Embo Reports 5, 1110–1116CrossRef

Carbone AL, Song M, Uhrich KE (2008) Iodinated salicylate-based poly(anhydride-esters) as radiopaque biomaterials. Biomacromolecules 9, 1604–1612CrossRef

Clark J, Summerton L, Smith E, Kampa E, Vidaurre R, Touraud E (2007) Discussion document on eco-pharmacostewardship. KNAPPE: Knowledge and Need Assessment on Pharmaceutical Products in Environmental Waters. http://www.knappe-eu.org/fichiers/47-D5.1%20Ecopharmacostewardship%20disc%20doc.pdf

Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK (2009) Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A (in press: 10.1021/pr900344m)

Connor S. Glaxo chief: Our drugs do not work on most patients. The Independent, Independent News and Media Limited, London, England, 8 December 2003 http://http://www.independent.co.uk/news/science/glaxo-chief-our-drugs-do-not-work-on-most-patients-575942.html

Constable DJC, Dunn PJ, Hayler JD, Humphrey GR, Leazer JLJ, Linderman RJ, Lorenz K, Manley J, Pearlman Ba, Wells A, Zaks A, Zhang TY (2007) Key Green Chemistry research areas – a perspective from pharmaceutical manufacturers. Green Chem 9, 411–420CrossRef

Costa LG, Eaton DL (eds.) (2005) Gene-Environment Interactions: Fundamentals of Ecogenetics. John Wiley & Sons, Hoboken, NJ

Crimmins WF (2001) Disposing of expired drugs: A matter of policy. J Am Vet Med Assoc 218, 10

Daemmrich A, Bowden ME (2005) Emergence of pharmaceutical science and industry: 1870–1930. Chem Eng News 83

Daughton CG (2002) Environmental stewardship and drugs as pollutants. The Lancet 360, 1035–1036CrossRef

Daughton CG (2003) Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rationale for and avenues toward a green pharmacy. Environ Health Perspect 111, 757–774CrossRef

Daughton CG (2004) PPCPs in the environment: Future research – beginning with the end always in mind. In: Kümmerer K (ed.) Pharmaceuticals in the Environment: Sources, Fate, Effects and Risks, 2nd edn. Springer, Berlin, Germany

Daughton CG (2007) Pharmaceuticals in the environment: Sources and their management. In: Petrovic M, Barcelo D (eds.) Analysis, Fate and Removal of Pharmaceuticals in the Water Cycle. Elsevier Science, Amsterdam

Daughton CG (2008) Pharmaceuticals as environmental pollutants: The ramifications for human exposure. In: Heggenhougen K, Quah S (eds.) International Encyclopedia of Public Health. Academic Press, Oxford, England

Daughton CG (2009) Chemicals from the practice of healthcare: Challenges and unknowns posed by residues in the environment. Environ Toxicol Chem 28, 2490–2494

Daughton CG, Brooks BW (2011 – tentative) Pharmaceutical active ingredients in aquatic organisms. In: Beyer WN, Meador J (eds.) Environmental Contaminants in Biota: Interpreting Tissue Concentrations, 2nd edn. Taylor and Francis, Boca Raton, FL

Daughton CG, Ruhoy IS (2008) The afterlife of drugs and the role of pharmecovigilance. Drug Safety 31, 1069–1082

Daughton CG, Ruhoy IS (2009) Environmental footprint of pharmaceuticals – the significance of factors beyond direct excretion to sewers. Environ Toxicol Chem 28, 2495–2521

DBU (2008) Strategies and perspectives for development, use and emission management of pharmaceuticals. 1st International Conference on Sustainable Pharmacy. Osnabrück, Germany, Deutsche Bundesstiftung Umwelt, 24–25 April. http://www.dbu.de/359.html

Ebi KL, Kovats RS, Menne B (2006) An approach for assessing human health vulnerability and public health interventions to adapt to climate change. Environ Health Perspect 114, 1930–1934CrossRef

Eckerman I, Martineus J-C (1997) Medicines and the environment – what do we know today? In: Gray M (ed.) Swedish Association of Physicians for the Environment. Stockholm, Sweden. http://www.dnsy.se/_upload/lfm/medicines%20and%20the%20environment.pdf

eHealth Initiative (2008) eHealth Initiative. eHealth Initiative, Foundation for eHealth Initiative. Washington, DC. http://www.ehealthinitiative.org/

Ekedahl A (2002) Statistics on local drug sales: A tool to identify problem areas and to follow effects of education on drug use. Doctoral Dissertation, Department of Community Medicine, Malmö University Hospital, Lund University, Lund, Sweden, 54 pp, http://www.lub.lu.se/luft/diss/med638.pdf

Fichana D (2005) Green Engineering and Gate-to-gate Life Cycle Assessments for Pharmaceutical Products. Masters Dissertation, Rowan University, 142 pp, http://www.rowan.edu/library//rowan_theses/RU2005/0045GREE.PDF

Fugh-Berman A (2009). Speaking of Medicine: Medicine Community Blog, PLoS. http://speakingofmedicine.plos.org/2009/08/07/ghostwriting-101/

Galagan Y, Su WF (2008) Fadable ink for time-temperature control of food freshness: Novel new time-temperature indicator. Food Res Int 41, 653–657CrossRef

Giacomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, Nakamura Y (2007) When good drugs go bad. Nature 446, 975–977CrossRef

Gorard DA (2006) Escalating polypharmacy. QJM 99, 797–800CrossRef

Gunnarsson B, Wennmalm A (2008) Drug design should involve consideration of environmental risk and hazard. Lett Drug Des Discov 5, 232–235CrossRef

HapMap (2008) International HapMap Project. The International HapMap Consortium. http://www.hapmap.org/

Haskell SRR, Ormond CJ, Occhipinti LP, Powers EL (2003) Waste management: Expired drugs. J Am Vet Med Assoc 223, 51–52CrossRef

Henderson RK, Jimenez-Gonzalez C, Preston C, Constable DJC, Woodley JM (2008) EHS & LCA assessment for 7-ACA synthesis. A case study for comparing biocatalytic & chemical synthesis. Ind Biotechnol 4, 180–192CrossRef

Hepler C, Strand L (1990) Opportunities and responsibilities in pharmaceutical care. Am J Health Syst Pharm 47, 533–543

HHS (2009) Nationwide Health Information Network (NHIN). U.S. Department of Health & Human Services. Washington, DC. http://healthit.hhs.gov/portal/server.pt?open=512&mode=2&cached=true&objID=1142

Hoekstra AY, Chapagain AK (2007) Water footprints of nations: Water use by people as a function of their consumption pattern. Water Resour Manage 21, 35–48CrossRef

Hudson KL, Holohan MK, Collins FS (2008) Keeping pace with the times – the genetic information nondiscrimination act of 2008. N Engl J Med 358, 2661–2663CrossRef

IMS (2008) IMS Health Forecasts 4.5 – 5.5 Percent Growth for Global Pharmaceutical Market in 2009, Exceeding $820 Billion. IMS Health Incorporated. http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=9e553599b554d110VgnVCM100000ed152ca2RCRD&vgnextfmt=default

IOM (2008) Knowing What Works in Health Care: A Roadmap for the Nation. Committee on Reviewing Evidence to Identify Highly Effective Clinical Services, Board on Health Care Services, Institute of Medicine, The National Academies Press, Eden J, Wheatley B, McNeil B, Sox H (ed). Washington, DC. http://www.nap.edu/catalog.php?record_id=12038

Joly BM, Polyak G, Davis MV, Brewster J, Tremain B, Raevsky C, Beitsch LM (2007) Linking accreditation and public health outcomes: A logic model approach. J Public Health Manag Pract 13, 349–356

Kaitin KI, (ed.) (2005) Drug safety withdrawals in the US not linked to speed of FDA approval. Tufts CSDD (Center for the Study of Drug Development) Impact Report 7, 1–4

Katsanis SH, Javitt G, Hudson K (2008) A case study of personalized medicine. Science 320, 53–54CrossRef

Keil F (2008 – August) Pharmaceuticals for Human Use: Options of Action for Reducing the Contamination of Water Bodies: A Practical Guide. Institute for Social-Ecological Research (ISOE) GmbH and Research Project start (“Management Strategies for Pharmaceutical Residues in Drinking Water”). Frankfurt/Main, Germany. https://http://www.start-project.de/downloads/start_Practical_Guide.pdf

Khetan SK, Collins TJ (2007) Human pharmaceuticals in the aquatic environment: A challenge to green chemistry. Chem Rev 107, 2319–2364CrossRef

Korobkin R, Rajkumar R (2008) The genetic information nondiscrimination act – a half-step toward risk sharing. N Engl J Med 359, 335–337CrossRef

Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M (2005) Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438, 685–689CrossRef

Kuehn BM (2008) Traces of drugs found in drinking water: Health effects unknown, safer disposal urged. J Am Med Assoc 299, 2011–2013CrossRef

Kümmerer K (2007) Sustainable from the very beginning: Rational design of molecules by life cycle engineering as an important approach for green pharmacy and green chemistry. Green Chem 9, 899–907CrossRef

Kümmerer K, Velo G (2006) Ecopharmacology: A new topic of importance in pharmacovigilance. Drug Saf 29, 371–373CrossRef

Kuspis DA, Krenzelok EP (1996) What happens to expired medications? A survey of community medication disposal. Vet Hum Toxicol 38, 48–49

Levy W (2008) Peptide progress: Refined manufacturing and delivery promises more advanced drug offerings. Pharm Formulation & Quality 10, 28–30, 32

Markle Foundation (2008) Connecting for Health. The Markle Foundation. http://www.connectingforhealth.org/

Martin-Calero MJ, Machuca M, Murillo MD, Cansino J, Gastelurrutia MA, Faus MJ (2004) Structural process and implementation programs of pharmaceutical care in different countries. Curr Pharm Des 10, 3969–3985CrossRef

Mayer LD, Janoff AS (2007) Optimizing combination chemotherapy by controlling drug ratios. Mol Interv 7, 216–223CrossRef

Microsoft (2009) Microsoft Amalga Unified Intelligence System 2009. Microsoft. http://www.microsoft.com/amalga/products/microsoftamalgauis/default.mspx

Mihelcic JR, Zimmerman JB, Ramaswami A (2007) Integrating developed and developing world knowledge into global discussions and strategies for sustainability. 1. Science and Technology. Environ Sci Technol 41, 3415–3421CrossRef

Moynihan R (2008) Key opinion leaders: Independent experts or drug representatives in disguise? British Medical Journal 336, 1402–1403CrossRef

NIH (2008) NIH Roadmap Initiatives. Office of Portfolio Analysis and Strategic Initiatives, National Institutes of Health Bethesda, Maryland. http://nihroadmap.nih.gov/initiativeslist.asp

Patz JA, Campbell-Lendrum D, Holloway T, Foley JA (2005) Impact of regional climate change on human health. Nature 438, 310–317CrossRef

Pearson GJ (2007) Evolution in the practice of pharmacy–not a revolution! CMAJ 176, 1295–1296CrossRef

Phillips DP, Barker GEC, Eguchi MM (2008) A steep increase in domestic fatal medication errors with use of alcohol and/or street drugs. Arch Intern Med 168, 1561–1566CrossRef

Pinheiro C (2008) Drug donations: What lies beneath. Bull World Health Organ 86, 580–581CrossRef

Pollack A. Pricing Pills by the Results. New York Times, New York Times, 14 July 2007 http://www.nytimes.com/2007/07/14/business/14drugprice.html?ref=health&pagewanted=all

PricewaterhouseCoopers (2005) Personalized medicine: The emerging pharmacogenomics revolution. PricewaterhouseCoopers GTC, Health Research Institute. http://www.pwc.com/techforecast/pdfs/pharmaco-wb-x.pdf

Rahman SZ, Khan RA (2006) Environmental pharmacology: A new discipline. Indian J Pharmacol 38, 229–230CrossRef

Rees WE (1992) Ecological footprints and appropriated carrying capacity: What urban economics leaves out. Environ Urban 4, 121–130CrossRef

Rosenberg J, Schilit S, Nathan J (2008) Which oral solid medications should be protected from light and/or moisture? Drug Topics 12 May, 25–27

Ruhoy IS, Daughton CG (2008) Beyond the medicine cabinet: An analysis of where and why medications accumulate. Environ Int 34, 1157–1169CrossRef

SACGHS (May 2008) Realizing the Potential of Pharmacogenomics: Opportunities and Challenges. Secretary’s Advisory Committee on Genetics, Health, and Society, chartered by U.S. Department of Health & Human Services (ed). http://www4.od.nih.gov/oba/sacghs/reports/SACGHS_PGx_Report.pdf

Sanderson K (2009) Big interest in heavy drugs. Nature 458, 269CrossRef

Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI, Ahmad N, Cui H, Mousa SA, Mukhtar H (2009) Introducing nanochemoprevention as a novel approach for cancer control: Proof of principle with green tea polyphenol Epigallocatechin-3-Gallate. Cancer Res 69, 1712–1716CrossRef

Sismondo S (2007) Ghost management: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med 4, e286CrossRef

Smolensky MH, Peppas NA (2007) Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev 59, 828–851CrossRef

Stockholm City Council (2008) Environmentally Classified Pharmaceuticals. http://www.janusinfo.se/imcms/servlet/GetDoc?meta_id=10205; via http://www.janusinfo.se/environment

Stoughton M, Votta T (2003) Implementing service-based chemical procurement: Lessons and results. J Cleaner Production 11, 839–849CrossRef

Surescripts (2009) 2008 National Progress Report on E-Prescribing. Alexandria, VA: Surescripts LLC. http://www.surescripts.com/downloads/NPR/national-progress-report.pdf

Thayer AM (2008) Filling a highly potent niche: Drug companies want to create conjugates of potent drugs and biological molecules, and custom manufacturers are complying. Chem Eng News 86, 28–32CrossRef

Tinetti ME (2008) Over-the-counter sales of statins and other drugs for asymptomatic conditions. N Engl J Med 358, 2728–2732CrossRef

Trusheim MR, Berndt ER, Douglas FL (2007) Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 6, 287–293CrossRef

Tucker JL (2006) Green chemistry, a pharmaceutical perspective. Org Process Res Dev 10, 315–319CrossRef

Tudor TL (2007) Towards the development of a standardised measurement unit for healthcare waste generation. Resour, Conserv Recycling 50, 319–333CrossRef

UNIDO (2008) Chemical Leasing. United Nations Industrial Development Organization. Vienna, Austria. http://www.chemicalleasing.com/

US Congress (24 June 2008) H.R. 6357: PRO(TECH)T Act of 2008 (“Protecting Records, Optimizing Treatment and Easing Communication through Healthcare Technology Act of 2008”) 110th Congress, 2D Session, Washington, DC

US EPA (2008a) Pharmaceuticals and Personal Care Products (PPCPs): Relevant Literature. US Environmental Protection Agency. http://www.epa.gov/ppcp/lit.html

US EPA (2008b) Green Chemistry Program at EPA. U.S. Environmental Protection Agency. http://www.epa.gov/gcc/pubs/epa_gc.html

US FDA (2008a) Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Rockville, MD. http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm

US FDA (2008b) FDA’s Sentinel Initiative: National Strategy for Monitoring Medical Product Safety. US Food and Drug Administration. http://www.fda.gov/oc/initiatives/advance/sentinel/

van Mil JWF, Schulz M, Tromp TFJD (2004) Pharmaceutical care, European developments in concepts, implementation, teaching, and research: A review. Pharm World & Sci 26, 303–311CrossRef

Venhuis BJ, Barends DM, Zwaagstra ME, de Kaste D (2007) Recent developments in counterfeits and imitations of Viagra, Cialis and Levitra: A 2005–2006 update. RIVM Report 370030001/2007. Bilthoven, the Netherlands: RIVM (Netherlands National Institute for Public Health and the Environment). http://rivm.openrepository.com/rivm/handle/10029/16459?mode=full

Warner S (2004) Diagnostics + therapy = theranostics. The Scientist 18, 38

White EV, Latif DA (2006) Office-based pharmacy practice: Past, present, and future. Ann Pharmacother 40, 1409–1414CrossRef

WHO (1999) Guidelines for safe disposal of unwanted pharmaceuticals in and after emergencies. World Health Organization. http://www.who.int/water_sanitation_health/medicalwaste/pharmaceuticals/en/index.html

WHO (2007) WHO core principles for achieving safe and sustainable management of health-care waste. World Health Organization, Department for Public Health and Environment, Assessing and Managing Environmental Risks to Health, WHO/SDE/WSH/07.10. http://www.who.int/water_sanitation_health/medicalwaste/hcwprinciples.pdf; http://www.who.int/water_sanitation_health/medicalwaste/hcwprinciples/en/index.html

WHO (2008a) “World directory of poisons centres (Yellow Tox)” International Programme on Chemical Safety (IPCS). The World Health Organization. Geneva, Switzerland. http://www.who.int/ipcs/poisons/centre/directory/en/

WHO (2008b) About the ATC/DDD system. The WHO Collaborating Centre for Drug Statistics Methodology. Oslo, Norway. http://www.whocc.no/atcddd/atcsystem.html

Woodend K (2003) Medication management: The future of pharmaceutical care? Can Pharm J (CPJ) 136, 29–31, 46

Woodley JM (2008) New opportunities for biocatalysis: Making pharmaceutical processes greener. Trends Biotechnol 26, 321–327CrossRef

Woodward KN (2005) Veterinary pharmacovigilance. Part 3. Adverse effects of veterinary medicinal products in animals and on the environment. J Vet Pharmacol Therapeut 28, 171–184CrossRef

Zed PJ, Abu-Laban RB, Balen RM, Loewen PS, Hohl CM, Brubacher JR Wilbur K, Wiens MO, Samoy LJ, Lacaria K, Purssell RA (2008) Incidence, severity and preventability of medication-related visits to the emergency department: A prospective study. CMAJ 178, 1563–1569CrossRef

Zuccato E, Calamari D, Natangelo M, Fanelli R (2000) Presence of therapeutic drugs in the environment. The Lancet 355, 1789–1790CrossRef

Titel: Reducing the Ecological Footprint of Pharmaceutical Usage: Linkages Between Healthcare Practices and the Environment
verfasst von: Christian G. Daughton
Ilene S. Ruhoy
Verlag: Springer Berlin Heidelberg
Buch: Green and Sustainable Pharmacy
Print ISBN: 978-3-642-05198-2

Electronic ISBN: 978-3-642-05199-9

Copyright-Jahr: 2010
DOI: https://doi.org/10.1007/978-3-642-05199-9_6